The Liposome regulatory update

LIPO said the FDA has accepted for filing an NDA the company submitted in May for ABLC, its amphotericin B lipid complex. LIPO is seeking approved to market ABLC to treat aspergillosis, a systemic fungal infection, in patients who have failed to respond to conventional antifungal agents or who are intolerant to such agents, or who have pre-existing renal impairment. ...